journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://read.qxmd.com/read/31300207/association-between-the-cervicovaginal-microbiome-brca1-mutation-status-and-risk-of-ovarian-cancer-a-case-control-study
#1
Nuno R Nené, Daniel Reisel, Andreas Leimbach, Dorella Franchi, Allison Jones, Iona Evans, Susanne Knapp, Andy Ryan, Shohreh Ghazali, John F Timms, Tobias Paprotka, Line Bjørge, Michal Zikan, David Cibula, Nicoletta Colombo, Martin Widschwendter
BACKGROUND: Various factors-including age, family history, inflammation, reproductive factors, and tubal ligation-modulate the risk of ovarian cancer. In this study, our aim was to establish whether women with, or at risk of developing, ovarian cancer have an imbalanced cervicovaginal microbiome. METHODS: We did a case-control study in two sets of women aged 18-87 years in the Czech Republic, Germany, Italy, Norway, and the UK. The ovarian cancer set comprised women with epithelial ovarian cancer and controls (both healthy controls and those diagnosed with benign gynaecological conditions)...
July 9, 2019: Lancet Oncology
https://read.qxmd.com/read/31300206/of-microbes-and-women-brca1-vaginal-microbiota-and-ovarian-cancer
#2
Hans Verstraelen
No abstract text is available yet for this article.
July 9, 2019: Lancet Oncology
https://read.qxmd.com/read/31296492/nanoparticle-augmentation-of-radiotherapy-in-sarcoma
#3
Daniel P Nussbaum
No abstract text is available yet for this article.
July 8, 2019: Lancet Oncology
https://read.qxmd.com/read/31296491/nbtxr3-a-first-in-class-radioenhancer-hafnium-oxide-nanoparticle-plus-radiotherapy-versus-radiotherapy-alone-in-patients-with-locally-advanced-soft-tissue-sarcoma-act-in-sarc-a-multicentre-phase-2-3-randomised-controlled-trial
#4
Sylvie Bonvalot, Piotr L Rutkowski, Juliette Thariat, Sébastien Carrère, Anne Ducassou, Marie-Pierre Sunyach, Peter Agoston, Angela Hong, Augustin Mervoyer, Marco Rastrelli, Victor Moreno, Rubi K Li, Béatrice Tiangco, Antonio Casado Herraez, Alessandro Gronchi, László Mangel, Teresa Sy-Ortin, Peter Hohenberger, Thierry de Baère, Axel Le Cesne, Sylvie Helfre, Esma Saada-Bouzid, Aneta Borkowska, Rodica Anghel, Ann Co, Michael Gebhart, Guy Kantor, Angel Montero, Herbert H Loong, Ramona Vergés, Lore Lapeire, Sorin Dema, Gabriel Kacso, Lyn Austen, Laurence Moureau-Zabotto, Vincent Servois, Eva Wardelmann, Philippe Terrier, Alexander J Lazar, Judith V M G Bovée, Cécile Le Péchoux, Zsusanna Papai
BACKGROUND: Pathological complete response to preoperative treatment in adults with soft-tissue sarcoma can be achieved in only a few patients receiving radiotherapy. This phase 2-3 trial evaluated the safety and efficacy of the hafnium oxide (HfO2 ) nanoparticle NBTXR3 activated by radiotherapy versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma. METHODS: Act.In.Sarc is a phase 2-3 randomised, multicentre, international trial...
July 8, 2019: Lancet Oncology
https://read.qxmd.com/read/31296490/the-fragility-of-phase-3-trials-supporting-fda-approved-anticancer-medicines-a-retrospective-analysis
#5
Joseph C Del Paggio, Ian F Tannock
BACKGROUND: The fragility index of trial results-ie, the minimum number of changes from non-events to events resulting in loss of statistical significance-can provide a measure of confidence that a positive effect reported in a randomised controlled trial is real. We aimed to calculate the fragility index of randomised controlled trials supporting US Food and Drug Administration (FDA)-approved anticancer drugs. METHODS: This is a retrospective analysis of phase 3, randomised, controlled trials supporting anticancer drugs that were approved by the FDA between Jan 1, 2014, and Dec 31, 2018...
July 8, 2019: Lancet Oncology
https://read.qxmd.com/read/31281098/clofarabine-and-cytarabine-for-acute-myeloid-leukaemia
#6
Robert Stirrups
No abstract text is available yet for this article.
July 4, 2019: Lancet Oncology
https://read.qxmd.com/read/31281097/carcinogenicity-of-night-shift-work
#7
(no author information available yet)
No abstract text is available yet for this article.
July 4, 2019: Lancet Oncology
https://read.qxmd.com/read/31281096/omitting-radiotherapy-after-head-and-neck-cancer-surgery
#8
Elizabeth Gourd
No abstract text is available yet for this article.
July 4, 2019: Lancet Oncology
https://read.qxmd.com/read/31262657/regorafenib-dose-optimisation-in-patients-with-refractory-metastatic-colorectal-cancer-redos-a-randomised-multicentre-open-label-phase-2-study
#9
Tanios S Bekaii-Saab, Fang-Shu Ou, Daniel H Ahn, Patrick M Boland, Kristen K Ciombor, Erica N Heying, Travis J Dockter, Nisha L Jacobs, Boris C Pasche, James M Cleary, Jeffrey P Meyers, Rodwige J Desnoyers, Jeannine S McCune, Katrina Pedersen, Afsaneh Barzi, E Gabriela Chiorean, Jeffrey Sloan, Mario E Lacouture, Heinz-Josef Lenz, Axel Grothey
BACKGROUND: Regorafenib confers an overall survival benefit in patients with refractory metastatic colorectal cancer; however, the adverse event profile of regorafenib has limited its use. Despite no supportive evidence, various dosing schedules are used clinically to alleviate toxicities. This study evaluated the safety and activity of two regorafenib dosing schedules. METHODS: In this randomised, multicentre, open-label, phase 2 study done in 39 outpatient cancer centres in the USA, adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy, including EGFR inhibitors if KRAS wild-type, were enrolled...
June 28, 2019: Lancet Oncology
https://read.qxmd.com/read/31262656/study-evidence-confirms-current-clinical-practice-in-refractory-metastatic-colorectal-cancer-the-redos-trial
#10
Ralf-Dieter Hofheinz, Sebastian Stintzing
No abstract text is available yet for this article.
June 28, 2019: Lancet Oncology
https://read.qxmd.com/read/31257180/lapatinib-with-chemotherapy-for-gastroesophageal-cancer
#11
Robert Stirrups
No abstract text is available yet for this article.
June 27, 2019: Lancet Oncology
https://read.qxmd.com/read/31257179/snmmi-2019-annual-meeting
#12
David Collingridge
No abstract text is available yet for this article.
June 27, 2019: Lancet Oncology
https://read.qxmd.com/read/31257178/a-new-agent-in-the-family-of-antibody-drug-conjugates
#13
Xavier Pivot, Thierry Petit
No abstract text is available yet for this article.
June 27, 2019: Lancet Oncology
https://read.qxmd.com/read/31257177/trastuzumab-duocarmazine-in-locally-advanced-and-metastatic-solid-tumours-and-her2-expressing-breast-cancer-a-phase-1-dose-escalation-and-dose-expansion-study
#14
Udai Banerji, Carla M L van Herpen, Cristina Saura, Fiona Thistlethwaite, Simon Lord, Victor Moreno, Iain R Macpherson, Valentina Boni, Christian Rolfo, Elisabeth G E de Vries, Sylvie Rottey, Jill Geenen, Ferry Eskens, Marta Gil-Martin, Ellen C Mommers, Norbert P Koper, Philippe Aftimos
BACKGROUND: Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. Preclinical studies showed promising antitumour activity in various models. In this first-in-human study, we assessed the safety and activity of trastuzumab duocarmazine in patients with advanced solid tumours. METHODS: We did a phase 1 dose-escalation and dose-expansion study. The dose-escalation cohort comprised patients aged 18 years or older enrolled from three academic hospitals in Belgium, the Netherlands, and the UK with locally advanced or metastatic solid tumours with variable HER2 status who were refractory to standard cancer treatment...
June 27, 2019: Lancet Oncology
https://read.qxmd.com/read/31255490/5-year-overall-survival-in-patients-with-lung-cancer-eligible-or-ineligible-for-screening-according-to-us-preventive-services-task-force-criteria-a-prospective-observational-cohort-study
#15
Yung-Hung Luo, Lei Luo, Jason A Wampfler, Yi Wang, Dan Liu, Yuh-Min Chen, Alex A Adjei, David E Midthun, Ping Yang
BACKGROUND: The US Preventive Services Task Force (USPSTF) recommends lung cancer screening among individuals aged 55-80 years with a 30 pack-year cigarette smoking history and, if they are former smokers, those who quit within the past 15 years. Our previous report found that two-thirds of newly diagnosed patients with lung cancer do not meet these criteria; they are reported to be either long-term quitters (≥15 years since quitting) or from a younger age group (age 50-54 years). We aimed to assess survival outcomes in these two subgroups...
June 26, 2019: Lancet Oncology
https://read.qxmd.com/read/31255489/improving-selection-of-individuals-into-lung-cancer-screening-programmes
#16
Christine D Berg
No abstract text is available yet for this article.
June 26, 2019: Lancet Oncology
https://read.qxmd.com/read/31253572/iph4102-a-first-in-class-anti-kir3dl2-monoclonal-antibody-in-patients-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma-an-international-first-in-human-open-label-phase-1-trial
#17
Martine Bagot, Pierluigi Porcu, Anne Marie-Cardine, Maxime Battistella, Basem M William, Maarten Vermeer, Sean Whittaker, Federico Rotolo, Caroline Ram-Wolff, Michael S Khodadoust, Armand Bensussan, Carine Paturel, Cecile Bonnafous, Helene Sicard, Hatem A Azim, Youn H Kim
BACKGROUND: IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form, Sézary syndrome. We aimed to assess the safety and activity of IPH4102 in cutaneous T-cell lymphoma. METHODS: We did an international, first-in-human, open-label, phase 1 clinical trial with dose-escalation and cohort-expansion parts in five academic hospitals in the USA, France, the UK, and the Netherlands...
June 25, 2019: Lancet Oncology
https://read.qxmd.com/read/31253571/anti-kir3dl2-therapy-in-the-treatment-of-s%C3%A3-zary-syndrome
#18
Pietro Quaglino
No abstract text is available yet for this article.
June 25, 2019: Lancet Oncology
https://read.qxmd.com/read/31221620/mri-versus-mammography-for-breast-cancer-screening-in-women-with-familial-risk-famrisc-a-multicentre-randomised-controlled-trial
#19
Sepideh Saadatmand, H Amarens Geuzinge, Emiel J T Rutgers, Ritse M Mann, Diderick B W de Roy van Zuidewijn, Harmien M Zonderland, Rob A E M Tollenaar, Marc B I Lobbes, Margreet G E M Ausems, Martijne van 't Riet, Maartje J Hooning, Ingeborg Mares-Engelberts, Ernest J T Luiten, Eveline A M Heijnsdijk, Cees Verhoef, Nico Karssemeijer, Jan C Oosterwijk, Inge-Marie Obdeijn, Harry J de Koning, Madeleine M A Tilanus-Linthorst
BACKGROUND: Approximately 15% of all breast cancers occur in women with a family history of breast cancer, but for whom no causative hereditary gene mutation has been found. Screening guidelines for women with familial risk of breast cancer differ between countries. We did a randomised controlled trial (FaMRIsc) to compare MRI screening with mammography in women with familial risk. METHODS: In this multicentre, randomised, controlled trial done in 12 hospitals in the Netherlands, women were eligible to participate if they were aged 30-55 years and had a cumulative lifetime breast cancer risk of at least 20% because of a familial predisposition, but were BRCA1, BRCA2, and TP53 wild-type...
June 17, 2019: Lancet Oncology
https://read.qxmd.com/read/31221619/epacadostat-plus-pembrolizumab-versus-placebo-plus-pembrolizumab-in-patients-with-unresectable-or-metastatic-melanoma-echo-301-keynote-252-a-phase-3-randomised-double-blind-study
#20
Georgina V Long, Reinhard Dummer, Omid Hamid, Thomas F Gajewski, Christian Caglevic, Stephane Dalle, Ana Arance, Matteo S Carlino, Jean-Jacques Grob, Tae Min Kim, Lev Demidov, Caroline Robert, James Larkin, James R Anderson, Janet Maleski, Mark Jones, Scott J Diede, Tara C Mitchell
BACKGROUND: Immunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumour activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma. In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab versus placebo plus pembrolizumab. METHODS: In this international, randomised, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAFV600 mutant status or consented to BRAFV600 mutation testing during screening...
June 17, 2019: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"